Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03286530 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
A Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia in Remission, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT03286530: Active Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia in Remission, sponsored by Massachusetts General Hospital.
NCT03286530 is a Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia in Remission that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 64 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (45% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03286530, a Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia in Remission, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib
Primary Outcome
The number of participants surviving after one year that have not experienced graft-versus-host disease (GVHD) or graft relapse (GRFS rate).
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (6)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Boston
Missouri
- Washington University - St Louis
Ohio
- The Ohio State University - Columbus
Tennessee
- Vanderbilt University - Nashville
Wisconsin
- Medical College of Wisconsin - Wauwatosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT03286530 still lists
NCT03286530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (45% lower).
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT03286530 lists 6 locations in 5 states (Massachusetts, Missouri, Ohio).
Frequently Asked Questions
What is clinical trial NCT03286530 about?
NCT03286530 is a clinical study titled "Ruxolitinib + Allogeneic Stem Cell Transplantation in AML". This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib
What is the current status of trial NCT03286530?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2017-11-03. Estimated completion is 2026-12.
What conditions does trial NCT03286530 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation.
What interventions are being tested in trial NCT03286530?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT03286530?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03286530 being conducted?
This trial has 6 study locations across Massachusetts, Missouri, Ohio, Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03286530's enrollment target sits among peer trials
64 115th of 306 higher than 192 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI